CLINICAL TRIALS PROFILE FOR ETANERCEPT

Biosimilar Clinical Trials for etanercept

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01891864 ↗	Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel	Completed	Hexal AG	Phase 3	2013-06-01	The purpose of this study is to demonstrate equivalent efficacy of GP2015 and Enbrel® in patients with moderate to severe chronic plaque-type psoriasis with respect to PASI 75 response rate at Week 12.
NCT01891864 ↗	Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel	Completed	Sandoz	Phase 3	2013-06-01	The purpose of this study is to demonstrate equivalent efficacy of GP2015 and Enbrel® in patients with moderate to severe chronic plaque-type psoriasis with respect to PASI 75 response rate at Week 12.
NCT03273088 ↗	Pharmacokinetic, Safety and Tolerability Study of Altebrel in Healthy Male Subjects	Completed	AryoGen Pharmed Co.	Phase 1	2016-12-04	This study aims to demonstrate pharmacokinetic (PK) similarity of biosimilar candidate Altebrel relative to etanercept reference product (Enbrel®) and evaluate safety and tolerability of Altebrel, in a crossover fashion in healthy male volunteers after administration of a single dose (25 mg) of etanercept. The primary objective of this study is to demonstrate that the PK of Altebrel is similar to its originator, Enbrel®, as assessed by the area under the serum concentration time curve (AUC) from time 0 extrapolated to infinity (AUCinf) and the Cmax. The secondary objectives of the study are: To further compare the PK of Altebrel and Enbrel®. To assess the safety of Altebrel.
NCT03880968 ↗	Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis	Completed	First Affiliated Hospital of Wenzhou Medical University		2012-03-01	Evaluate the disease activity guided tapering and discontinuation strategies of etanercept (ETN) in patients with ankylosing spondylitis (AS) in 48 weeks.
NCT03880968 ↗	Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis	Completed	Ningbo Medical Center Lihuili Hospital		2012-03-01	Evaluate the disease activity guided tapering and discontinuation strategies of etanercept (ETN) in patients with ankylosing spondylitis (AS) in 48 weeks.
NCT03880968 ↗	Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis	Completed	Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine		2012-03-01	Evaluate the disease activity guided tapering and discontinuation strategies of etanercept (ETN) in patients with ankylosing spondylitis (AS) in 48 weeks.

All Clinical Trials for etanercept

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000433 ↗	Blocking Tumor Necrosis Factor in Ankylosing Spondylitis	Completed	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 2	1999-10-01	The Division of Rheumatology at University of California San Francisco is conducting a research study on the treatment of ankylosing spondylitis (AS) with a new therapy currently used for people with other forms of arthritis. The drug, called Enbrel (or etanercept), is a protein that is given twice weekly by injection underneath the skin. It blocks the action of tumor necrosis factor-alpha (TNF-alpha), a substance that may be involved in AS, rheumatoid arthritis, and other inflammatory conditions. We will randomly assign patients to receive either the drug or a placebo (inactive treatment) for 4 months. The results we will monitor include morning stiffness, spinal mobility, activities of daily life, and safety of the drug.
NCT00001862 ↗	TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis	Completed	National Eye Institute (NEI)	Phase 2	1999-02-01	This study will investigate the safety and effectiveness of the drug TNFR:Fc to treat uveitis (eye inflammation) in patients with juvenile rheumatoid arthritis. In other studies, TNFR:Fc significantly reduced joint pain and swelling in adult patients with rheumatoid arthritis, and the Food and Drug Administration has approved the drug for that use. Because medicines for arthritis often help patients with eye inflammation, this study will examine whether TNFR:Fc can help patients with uveitis. Patients with uveitis who are not responding well to standard treatment, such as steroids, and patients who have side effects from other medicines used to treat their uveitis or have refused treatment because of possible side effects may be eligible for this study. Candidates will be screened with a medical history, physical examination, and eye examination. The eye exam includes a check of vision and eye pressure, examination of the back of the eye (retina), and front of the eye, including measurements of protein and inflammation. Candidates will also undergo fluorescein angiography-a procedure in which photographs are taken of the retina to see if there is any leakage in the eye's blood vessels. A blood test and joint evaluation will also be done. Study participants will be given a shot of TNFR:Fc twice a week for up to 12 months and may continue other medicines they may be taking, such as prednisone or methotrexate. They will have follow-up examinations at week two and months one, two, three and four. Those who wish to continue treatment after the fourth month can receive the drug for another eight months and will have follow-up exams at months six, nine and 12, and one month after treatment ends. Each follow-up visit will include a repeat of the screening exams and an evaluation of side effects or discomfort from the medicine.
NCT00001901 ↗	Etanercept to Treat Wegener's Granulomatosis	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1999-02-01	This study will examine the use of etanercept (also called Enbrel or TNFR:Fc) in patients with Wegener's granulomatosis, a type of vasculitis (blood vessel inflammation). Wegener's granulomatosis may affect many parts of the body, including the brain, nerves, eyes, sinuses, lungs, kidneys, intestinal tract, skin, joints, heart, and other sites. Generally, the greater the disease involvement, the more life-threatening it is. Standard treatment is a combination of prednisone and a cytotoxic agent-usually cyclophosphamide or methotrexate. However, many patients treated with this regimen have a disease relapse, and others cannot take these drugs because of severe side effects. This study will evaluate etanercept's safety and effectiveness, and particularly its value in reducing the need for prednisone and preventing disease relapse. The Food and Drug Administration has approved etanercept for treating rheumatoid arthritis, another inflammatory disease. The drug works by blocking the activity of TNF-a protein made by white blood cells that is involved in the inflammatory process. Since prednisone also affects inflammatory proteins and lowers TNF production, the use of etanercept may reduce the need for prednisone in patients with Wegener's granulomatosis, and thus the risk of its side effects. Patients between 10 and 70 years of age with Wegener's granulomatosis who have never taken prednisone, methotrexate or cyclophosphamide, or have taken these drugs for less than 3 weeks may be eligible for this study. Participants will have a medical history review and physical examination, including laboratory studies. If medically indicated, X-rays, consultations and biopsies (surgical removal of a small tissue sample) of affected organs will also be done. All patients will begin treatment with prednisone, methotrexate and etanercept. Those who improve on this regimen will stop prednisone gradually over 3 months. Those who achieve disease remission at the end of another 3 months will be randomly assigned to either continue taking etanercept and methotrexate for another 12 months or to stop etanercept and continue only methotrexate for the next 12 months (after which methotrexate will gradually be stopped). Patients who are not in remission by the 6-month point will continue taking etanercept until they go into remission, when they will be assigned to stop or not stop etanercept, as described above. Patients who do not achieve remission within 12 months of beginning treatment will be taken off the study. Patients who have a disease relapse while on the study will likely be switched to treatment with prednisone and either methotrexate or cyclophosphamide. Patients randomized to stop etanercept and who have a relapse within a year of stopping the drug may be offered re-treatment on this protocol, but with continuing etanercept for a full year after remission. Patients will be evaluated in the outpatient clinic every 2 to 4 weeks for the first 4 months and every 1 to 3 months after that. Patients whose disease is in remission and who stop all medications will be followed every 3 to 6 months for 2 years. Follow-up evaluations include a physical examination, blood draws and, if medically indicated, X-rays. The total study duration is 60 to 70 months.
NCT00001954 ↗	Etanercept Therapy for Sjogren's Syndrome	Completed	National Institute of Dental and Craniofacial Research (NIDCR)	Phase 2	1999-12-01	This study will test the effectiveness of etanercept (Enbrel) for treating Sjogren's syndrome-an autoimmune disease that affects the secreting glands. (In autoimmune diseases, the immune system attacks the body's own tissues.) Reduced lacrimal (tear) gland function causes dry eyes with a scratchy sensation, and, in severe cases, vision be may impaired. Reduced salivary gland function causes dry mouth, resulting in greatly increased tooth decay. Dry mouth also makes chewing and swallowing difficult, which may lead to nutrition deficiencies. Sjogren's syndrome can also cause dryness of the skin and of mucous membranes in the nose, throat, airways, and vagina. Patients with Sjogren's syndrome who have had oral and eye examinations under NIDCR's protocol 84-D-0056 may participate in this study. Participants will be randomly assigned to receive either etanercept or placebo (an inactive look-alike substance) by injection under the skin twice a week for 3 months. Patients will be seen for evaluation before treatment begins (baseline) and again at 1, 3, and 4 months. The baseline and 3-month visits include a physical examination, eye examination, saliva collection from salivary glands, blood tests, and evaluation for changes in symptoms and treatment side effects. The 1- and 4-month visits include saliva collection, blood tests, and review of symptoms and treatment side effects. In addition, blood will be drawn every 2 weeks for safety monitoring. Patients will also be surveyed weekly (by telephone or during the clinic visit) about symptoms and treatment side effects. The Food and Drug Administration has approved Enbrel for treating certain forms of arthritis, which, like Sjogren's syndrome, are autoimmune disorders of the connective tissue. Laboratory studies also indicate that etanercept may be an effective treatment for Sjogren's syndrome.
NCT00001955 ↗	Study of Etanercept and Celecoxib to Treat Temporomandibular Disorders (Painful Joint Conditions)	Completed	National Institute of Dental and Craniofacial Research (NIDCR)	Phase 2	1999-12-01	This 2-part study will evaluate the effectiveness and side effects of two anti-inflammatory drugs for relieving pain and improving jaw function in patients with temporomandibular disorder (TMD). Part 1 will evaluate celecoxib (Celebrex); Part 2 will evaluate etanercept (Enbrel). The Food and Drug Administration has approved both of these drugs for treating certain forms of arthritis. Patients between the ages of 18 and 65 years with painful jaw joint conditions may be eligible for this study. Candidates will complete several written questionnaires about their jaw condition and will undergo a medical history, complete TMD evaluation, blood and urine tests, and imaging studies of the temporomandibular joint, such as X-rays and magnetic resonance imaging. Patients will rate the quality and intensity of their pain before beginning treatment. At certain periods during the study, they will also keep a pain diary, twice a day recording the intensity and magnitude of their pain. Part 1 - Celecoxib: Patients will be randomly assigned to receive either 1) celecoxib twice a day by mouth; 2) naproxen (a non-steroidal anti-inflammatory drug) twice a day by mouth; or 3) a placebo (inactive pill) twice a day by mouth. Part 2 - Etanercept: Patients will be randomly assigned to receive either 1) etanercept injected under the skin or 2) saline (an inactive placebo) injected under the skin. Patients in this group will also undergo two aspirations of fluid from the jaw joint - once before treatment begins and again 6 weeks later. For this procedure, the joint is numbed with an anesthetic and then a needle is inserted into the jaw space to withdraw fluid, which will be analyzed for inflammatory processes in the joint. All patients will have a final evaluation 6 weeks after beginning treatment, including a TMD physical examination, laboratory and X-ray tests as required. The pain diary and questionnaires will be collected at this visit.
NCT00005007 ↗	Etanercept for Wegener's Granulomatosis	Completed	FDA Office of Orphan Products Development	Phase 2/Phase 3	2000-06-01	This study will determine if the drug etanercept, also called Enbrel, is effective in producing and maintaining remission (reduction of disease symptoms) of Wegener's granulomatosis (WG). Etanercept blocks the action of tumor necrosis factor-alpha, a substance that may be involved in inflammatory conditions such as WG. Eight clinical centers around the United States will enroll 181 people who have WG. Patients will have an equal chance to receive either etanercept or placebo (inactive treatment). We will treat patients with standard medications for WG in addition to either etanercept or placebo. We will treat all patients with tapering doses of corticosteroids. After the patients' disease is controlled (in remission), we will reduce the dosages of the standard medications to lower the risk of side effects associated with these drugs. During the study, we will collect and save blood and tissues samples from patients and use the samples to address other medical questions, such as the cause of WG and factors that lead to disease progression.

Clinical Trial Conditions for etanercept

Condition Name

Condition Name for etanercept
Intervention	Trials
Rheumatoid Arthritis	100
Psoriasis	61
Ankylosing Spondylitis	27
Psoriatic Arthritis	17

Condition MeSH

Condition MeSH for etanercept
Intervention	Trials
Arthritis	149
Arthritis, Rheumatoid	123
Psoriasis	86
Spondylitis, Ankylosing	38

Clinical Trial Locations for etanercept

Trials by Country

Trials by Country for etanercept
Location	Trials
Canada	156
Spain	98
Japan	76
United Kingdom	73
Germany	65

Trials by US State

Trials by US State for etanercept
Location	Trials
California	66
New York	56
Florida	53
Texas	51
Pennsylvania	42

Clinical Trial Progress for etanercept

Clinical Trial Phase

Clinical Trial Phase for etanercept
Clinical Trial Phase	Trials
PHASE4	2
PHASE3	1
PHASE2	1

Clinical Trial Status

Clinical Trial Status for etanercept
Clinical Trial Phase	Trials
Completed	262
Unknown status	33
RECRUITING	31

Clinical Trial Sponsors for etanercept

Sponsor Name

Sponsor Name for etanercept
Sponsor	Trials
Amgen	70
Wyeth is now a wholly owned subsidiary of Pfizer	51
Pfizer	46

Sponsor Type

Sponsor Type for etanercept
Sponsor	Trials
Other	338
Industry	289
NIH	42

Last updated: April 30, 2026

Etanercept: Clinical Trials Update, Market Analysis, and 2030 Projection

What is etanercept and what formulations matter commercially?

Etanercept is a TNF-alpha (TNF-α) fusion protein used for autoimmune inflammatory diseases. The commercial landscape centers on multiple brands and biosimilar pathways across the U.S., EU, and other major markets.

Key marketed product lines

• Originator: Enbrel (etanercept)
• Europe (representative brand availability): Benepali, other etanercept biosimilars depending on country/regulator
• U.S.: Enbrel and multiple approved etanercept biosimilars (formulation and interchangeability status differs by label and payer policy by line of business)

Commercially relevant variable: etanercept’s IP and exclusivity are now largely product-lifecycle constrained by biosimilar entry, switching pressure, and contract-led tendering, not by primary innovation cycles.

---

What is the current state of clinical development for etanercept?

Etanercept’s clinical pipeline is now dominated by:

1. label expansion in specific patient subgroups or disease phenotypes,
2. comparative effectiveness or real-world evidence generation tied to payer endpoints,
3. biosimilar/next-generation comparability studies (where required) and post-approval pharmacovigilance.

Clinical-trial signals that continue to drive decision-making

• Ongoing trials typically target rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and juvenile idiopathic arthritis (JIA) subtypes.
• Trial designs skew toward treatment-naïve versus switch populations, and endpoints increasingly reflect tolerability, durability, and disease activity metrics rather than new MoA biology.

Evidence type driving near-term value

• After biosimilar penetration, the most material clinical “updates” for investors usually come from switching outcomes, adherence, and discontinuation rates in registries and claims-based studies, rather than new mechanism-of-action differentiation.

---

Which clinical endpoints and comparators define etanercept’s competitive positioning?

Etanercept is evaluated across:

• RA: ACR responses (ACR20/50/70), DAS28, CDAI/SDAI, and radiographic progression where applicable
• PsA and AS: ACR/PsARC-related endpoints, BASDAI/BASFI measures, enthesitis/dactylitis activity, and functional outcomes
• Safety: serious infection rates, malignancy signals, immunogenicity, injection-site reactions, and immunogenicity-associated loss of response

Comparator pressure

• In practice, etanercept competes against:
  • other TNF inhibitors (including higher-rebasing dosing and dosing convenience)
  • non-TNF biologics (IL-17, IL-12/23, IL-23, JAK inhibitors depending on indication and line of therapy)
  • combination strategies and sequencing patterns shaped by guidelines and payer policies

---

Where does etanercept sit in the market structure today?

Etanercept’s market position is shaped by four forces:

1. Biosimilar adoption and contract formularies
2. Class competition from multiple biologic and oral platforms
3. Switching behavior driven by pharmacy benefit design
4. Indication breadth (multiple autoimmune indications anchor baseline demand)

Implication: the commercial question is less “will etanercept have clinical efficacy” and more “will it retain share versus newer convenience and payer-preferred agents.”

---

How big is etanercept’s global market and what segments matter most?

Demand drivers

• Chronicity and long treatment duration in RA, PsA, AS, and JIA
• Continued guideline inclusion for TNF inhibitor-naïve and TNF-experienced populations
• Pediatric demand via JIA endpoints and continued reimbursement in many geographies

Where share is most fragile

• Later-line RA and PsA where JAK inhibitors and IL-17/IL-23 axis agents can displace TNF inhibitors
• Markets with aggressive biosimilar tendering, where price compression increases but volume share can still rise if switching is managed

---

What does the pricing and access environment look like?

Etanercept’s pricing is governed by:

• Reference pricing and tendering
• Biosimilar contracting that can force large discounts
• Switch policies based on pharmacy benefit design and interchangeability frameworks

Market behavior pattern

• As biosimilars gain footprint, the “premium” for brand-originator typically collapses first in high-tender markets.
• Over time, volume can stabilize or grow even as net unit price falls, depending on competitor class dynamics.

---

What is the 2030 projection for etanercept?

Projection framework (market-level)

• Unit volumes: likely stable-to-moderately growing in core indications under biosimilar-led continuation
• Net revenues: constrained by price erosion from biosimilar competition and active comparator substitution

Base-case directional forecast

• Global net sales through 2030: declines in nominal terms versus peak originator-era levels, with partial stabilization as etanercept retains share in RA, PsA, AS, and JIA where payer preferences favor established TNF options.

Why the direction stays negative but not necessarily steep

• Etanercept does not face extinction risk because it is entrenched in multiple indications.
• Displacement is offset by biosimilar affordability and broad clinical familiarity.

---

How do biosimilars change the revenue math for etanercept?

Biosimilar entry changes the market in three ways:

1. Average selling price (ASP) compression accelerates
2. Switching increases because payer formularies reduce “treatment inertia”
3. Differentiation shifts toward supply reliability, rebate structure, and patient support programs

Strategic outcome

• Growth becomes less about new patients and more about retaining treated patient cohorts and winning switch programs.

---

Competitive benchmark: where does etanercept face hardest displacement?

In each indication, competitive pressure rises as alternative modes and dosing schedules become payer-favored.

Most displacement risk

• RA lines where oral small molecules and non-TNF biologics gain preferred status
• PsA with IL-17/23 class agents where efficacy in skin and enthesitis drives prescribing
• Markets where TNF inhibitors are deprioritized in later lines due to formulary economics

Relative resilience

• JIA, where established pediatric pathways and dosing familiarity can support continuity
• AS in payer environments that keep TNF inhibitors as cost-effective anchors

---

What would matter most for a 12- to 24-month investment or R&D decision?

1. Evidence of durability and switching outcomes in RA/PsA registries after biosimilar adoption
2. Net revenue trajectory by geography (tender intensity is the main driver)
3. Share losses to specific classes by line of therapy, especially where guidelines changed in the past cycles
4. Safety and immunogenicity monitoring as biosimilar uptake increases, because payer trust and persistence depend on real-world tolerability

---

Key Takeaways

• Etanercept’s near-term clinical development is incremental and dominated by label/study needs and biosimilar ecosystem requirements rather than new MoA breakthroughs.
• The market is driven by chronic use across RA, PsA, AS, and JIA, but revenue is constrained by biosimilar price erosion and class competition.
• The 2030 outlook is directional: nominal sales likely trend down from peak brand-era levels, with volume potentially stabilizing under biosimilar affordability and payer switching programs.
• The highest-stakes variable is payer-led switching and tender intensity, not clinical efficacy.

---

FAQs

1) Is etanercept still competitive versus newer biologics and JAK inhibitors?

Yes in core TNF-inhibitor-aligned segments, especially where payer economics and established switching protocols favor TNF inhibitors, but share can erode in lines where non-TNF biologics or JAK inhibitors become preferred.

2) What most affects etanercept revenue in biosimilar markets?

Average selling price compression from contract-led biosimilar competition, offset in part by volume retention and continued persistence in chronic indications.

3) Which indications are most important to defend?

RA, PsA, AS, and JIA, with JIA often supporting persistence due to entrenched pediatric treatment pathways.

4) What is the main clinical evidence gap now?

Real-world comparative effectiveness and persistence after biosimilar switching, including safety outcomes that affect payer and provider confidence.

5) What is the 2030 risk factor most likely to change the forecast direction?

A payer-level formulary shift that accelerates displacement toward specific non-TNF classes or oral therapies in later-line disease management, combined with faster-than-expected ASP declines.

---

References

[1] FDA. (n.d.). Enbrel (etanercept) prescribing information and related product labeling. U.S. Food and Drug Administration.
[2] EMA. (n.d.). Enbrel and biosimilar etanercept product information (EPARs and assessments). European Medicines Agency.
[3] ClinicalTrials.gov. (n.d.). Etanercept clinical studies and results (search: etanercept). National Library of Medicine.
[4] WHO Collaborating Centre for Drug Statistics Methodology. (n.d.). ATC/DDD methodology and utilization context for TNF inhibitors. World Health Organization.
[5] Evidence-based rheumatology guidelines (RA, PsA, AS, and JIA) from major societies (e.g., ACR, EULAR) for therapeutic sequencing and TNF inhibitor positioning.